PortfoliosLab logoPortfoliosLab logo
SBIO vs. SURI
Performance
Return for Risk
Drawdowns
Volatility
Dividends

Performance

SBIO vs. SURI - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in ALPS Medical Breakthroughs ETF (SBIO) and Simplify Propel Opportunities ETF (SURI). The values are adjusted to include any dividend payments, if applicable.

Loading charts...

Returns By Period

In the year-to-date period, SBIO achieves a -0.39% return, which is significantly lower than SURI's 6.10% return.


SBIO

1D
1.41%
1M
-7.56%
YTD
-0.39%
6M
3.05%
1Y
65.41%
3Y*
17.80%
5Y*
2.68%
10Y*
8.02%

SURI

1D
-1.15%
1M
-2.84%
YTD
6.10%
6M
3.98%
1Y
32.89%
3Y*
6.93%
5Y*
10Y*
*Multi-year figures are annualized to reflect compound growth (CAGR)

SBIO vs. SURI - Yearly Performance Comparison


2026 (YTD)202520242023
SBIO
ALPS Medical Breakthroughs ETF
-0.39%55.07%3.81%4.17%
SURI
Simplify Propel Opportunities ETF
6.10%28.32%-13.34%-2.87%

Correlation

The correlation between SBIO and SURI is 0.55, which is moderate. They share some common price drivers but move independently often enough to provide real diversification benefit when combined.


Correlation
Correlation (1Y)
Calculated over the trailing 1-year period

0.55

Correlation (3Y)
Calculated over the trailing 3-year period

0.68

Correlation (All Time)
Calculated using the full available price history since Feb 9, 2023

0.69

The correlation between SBIO and SURI shifts across timeframes, from 0.55 (1 year) to 0.69 (all time), reflecting how their relationship changes across market environments.

SBIO vs. SURI - Sectors Allocation Comparison


Sectors
SBIO
SURI

Healthcare

100.0%
56.4%

Basic Materials

-

-

Communication Services

-

-

Consumer Cyclical

-

-

Consumer Defensive

-

-

Energy

-

43.6%

Industrials

-

-

Real Estate

-

-

Technology

-

-

Utilities

-

-

Financial Services

-0.0%

-

Healthcare

SBIO
100.0%
SURI
56.4%

Basic Materials

SBIO

-

SURI

-

Communication Services

SBIO

-

SURI

-

Consumer Cyclical

SBIO

-

SURI

-

Consumer Defensive

SBIO

-

SURI

-

Energy

SBIO

-

SURI
43.6%

Industrials

SBIO

-

SURI

-

Real Estate

SBIO

-

SURI

-

Technology

SBIO

-

SURI

-

Utilities

SBIO

-

SURI

-

Financial Services

SBIO
-0.0%
SURI

-

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Return for Risk

SBIO vs. SURI — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

SBIO
SBIO Risk / Return Rank: 7272
Overall Rank
SBIO Sharpe Ratio Rank: 6767
Sharpe Ratio Rank
SBIO Sortino Ratio Rank: 6767
Sortino Ratio Rank
SBIO Omega Ratio Rank: 5959
Omega Ratio Rank
SBIO Calmar Ratio Rank: 8888
Calmar Ratio Rank
SBIO Martin Ratio Rank: 7979
Martin Ratio Rank

SURI
SURI Risk / Return Rank: 4545
Overall Rank
SURI Sharpe Ratio Rank: 4141
Sharpe Ratio Rank
SURI Sortino Ratio Rank: 4242
Sortino Ratio Rank
SURI Omega Ratio Rank: 3939
Omega Ratio Rank
SURI Calmar Ratio Rank: 5757
Calmar Ratio Rank
SURI Martin Ratio Rank: 4848
Martin Ratio Rank
The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

SBIO vs. SURI - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for ALPS Medical Breakthroughs ETF (SBIO) and Simplify Propel Opportunities ETF (SURI). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.


SBIOSURIDifference
Sharpe ratioReturn per unit of total volatility

+0.79

Sortino ratioReturn per unit of downside risk

+1.00

Omega ratioGain probability vs. loss probability

1.36

1.26

+0.10

Calmar ratioReturn relative to maximum drawdown

5.19

2.81

+2.39

Martin ratioReturn relative to average drawdown

15.57

7.91

+7.65

SBIO vs. SURI - Sharpe Ratio Comparison

The current SBIO Sharpe Ratio is 2.24, which is higher than the SURI Sharpe Ratio of 1.46. The chart below compares the historical Sharpe Ratios of SBIO and SURI, calculated using daily returns over the previous 12 months. A higher Sharpe Ratio indicates better risk-adjusted performance relative to the risk-free rate.


Loading charts...

Sharpe Ratios by Period


SBIOSURIDifference

Sharpe Ratio (1Y)

Calculated over the trailing 1-year period

2.24

1.46

+0.79

Sharpe Ratio (5Y)

Calculated over the trailing 5-year period

0.08

Sharpe Ratio (10Y)

Calculated over the trailing 10-year period

0.24

Sharpe Ratio (All Time)

Calculated using the full available price history

0.21

0.15

+0.07

Drawdowns

SBIO vs. SURI - Drawdown Comparison

The maximum SBIO drawdown since its inception was -63.06%, which is greater than SURI's maximum drawdown of -47.76%. Use the drawdown chart below to compare losses from any high point for SBIO and SURI.


Loading charts...

Drawdown Indicators


SBIOSURIDifference

Max Drawdown

Largest peak-to-trough decline

-63.06%

-47.76%

-15.30%

Max Drawdown (1Y)

Largest decline over 1 year

-12.66%

-11.78%

-0.88%

Max Drawdown (3Y)

Largest decline over 3 years

-42.44%

-47.76%

+5.32%

Max Drawdown (5Y)

Largest decline over 5 years

-53.10%

Max Drawdown (10Y)

Largest decline over 10 years

-63.06%

Current Drawdown

Current decline from peak

-16.79%

-17.46%

+0.67%

Average Drawdown

Average peak-to-trough decline

-28.45%

-17.37%

-11.08%

Ulcer Index

Depth and duration of drawdowns from previous peaks

4.22%

4.17%

+0.05%

Volatility

SBIO vs. SURI - Volatility Comparison

ALPS Medical Breakthroughs ETF (SBIO) has a higher volatility of 9.48% compared to Simplify Propel Opportunities ETF (SURI) at 5.89%. This indicates that SBIO's price experiences larger fluctuations and is considered to be riskier than SURI based on this measure. The chart below showcases a comparison of their rolling one-month volatility.


Loading charts...

Volatility by Period


SBIOSURIDifference

Volatility (1M)

Calculated over the trailing 1-month period

9.48%

5.89%

+3.59%

Volatility (6M)

Calculated over the trailing 6-month period

22.70%

14.29%

+8.41%

Volatility (1Y)

Calculated over the trailing 1-year period

29.42%

22.79%

+6.63%

Volatility (5Y)

Calculated over the trailing 5-year period, annualized

33.56%

28.27%

+5.29%

Volatility (10Y)

Calculated over the trailing 10-year period, annualized

33.17%

28.27%

+4.90%

SBIO vs. SURI - Expense Ratio Comparison

SBIO has a 0.50% expense ratio, which is lower than SURI's 2.51% expense ratio.


Dividends

SBIO vs. SURI - Dividend Comparison

SBIO has not paid dividends to shareholders, while SURI's dividend yield for the trailing twelve months is around 16.04%.


PositionTTM202520242023202220212020201920182017
SBIO
ALPS Medical Breakthroughs ETF
0.00%0.00%3.55%0.22%0.00%0.00%0.00%0.04%2.79%1.77%
SURI
Simplify Propel Opportunities ETF
16.04%16.31%21.41%14.71%0.00%0.00%0.00%0.00%0.00%0.00%

Frequently Asked Questions


SBIO and SURI have a correlation of 0.55, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.

SBIO has higher volatility (9.48%) compared to SURI (5.89%). In terms of maximum drawdown, SBIO dropped -63.06% vs SURI's -47.76%.

On 3-year performance, SBIO leads with 17.80% vs 6.93% for SURI. On fees, SBIO is cheaper at 0.50% per year. On volatility, SURI has been the lower-risk option at 5.89%. The better choice depends on whether you care most about return, fees, risk, or income.

Over the 3-year period, SBIO has performed better with a 17.80% return vs 6.93%. Past performance does not guarantee future results, so compare this with risk, fees, and fund exposure.

SBIO is cheaper with a 0.50% expense ratio, compared with 2.51% for SURI.

SURI has the higher dividend yield at 16.04%, compared with 0.00% for SBIO.

They also come from different issuers: SS&C and Simplify. Their fees differ too: 0.50% for SBIO and 2.51% for SURI.

SBIO currently has the higher Sharpe Ratio (2.24 vs 1.46), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.

Portfolio Optimizer

Find the right allocation for SBIO and SURI

Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.

Open Portfolio Optimizer